Brian A. Whiteman

Array ( [id] => 18754368 [patent_doc_number] => 20230357776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION [patent_app_type] => utility [patent_app_number] => 18/320948 [patent_app_country] => US [patent_app_date] => 2023-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18320948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083379 [patent_doc_number] => 20240110180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES [patent_app_type] => utility [patent_app_number] => 18/199390 [patent_app_country] => US [patent_app_date] => 2023-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18199390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784653 [patent_doc_number] => 20230372245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY [patent_app_type] => utility [patent_app_number] => 18/317924 [patent_app_country] => US [patent_app_date] => 2023-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18317924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19027480 [patent_doc_number] => 11926827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-12 [patent_title] => MAPT RNA interference agents [patent_app_type] => utility [patent_app_number] => 18/311354 [patent_app_country] => US [patent_app_date] => 2023-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38817 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18764235 [patent_doc_number] => 11814622 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => OPA1 antisense oligomers for treatment of conditions and diseases [patent_app_type] => utility [patent_app_number] => 18/304878 [patent_app_country] => US [patent_app_date] => 2023-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 76 [patent_no_of_words] => 58708 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18771151 [patent_doc_number] => 20230365962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => TARGETED RNA EDITING BY LEVERAGING ENDOGENOUS ADAR USING ENGINEERED RNAS [patent_app_type] => utility [patent_app_number] => 18/303505 [patent_app_country] => US [patent_app_date] => 2023-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955512 [patent_doc_number] => 20240043839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => IHH AS A BIOMARKER AND THERAPEUTIC TARGET FOR NONALCOHOLIC STEATOHEPATITIS (NASH) [patent_app_type] => utility [patent_app_number] => 18/299799 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18751608 [patent_doc_number] => 20230354822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => SYSTEMS, METHODS AND COMPOSITION OF USING RNASE III MUTANTS TO PRODUCE SRNA TO CONTROL HOST PATHOGEN INFECTION [patent_app_type] => utility [patent_app_number] => 18/299121 [patent_app_country] => US [patent_app_date] => 2023-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769363 [patent_doc_number] => 20230364123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/132283 [patent_app_country] => US [patent_app_date] => 2023-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18132283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769362 [patent_doc_number] => 20230364122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/132253 [patent_app_country] => US [patent_app_date] => 2023-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18132253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582864 [patent_doc_number] => 20230265120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => NUCLEOSIDE DERIVATIVE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/186235 [patent_app_country] => US [patent_app_date] => 2023-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 203 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18186235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097765 [patent_doc_number] => 20240116993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/186919 [patent_app_country] => US [patent_app_date] => 2023-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18186919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19381261 [patent_doc_number] => 20240271131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => CHEMICALLY MODIFIED SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 18/185929 [patent_app_country] => US [patent_app_date] => 2023-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18185929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709541 [patent_doc_number] => 20230332161 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => BUILDING DESIGNER RNA NANO-STRUCTURES FOR SYNTHETIC BIOLOGY APPLICATIONS [patent_app_type] => utility [patent_app_number] => 18/176868 [patent_app_country] => US [patent_app_date] => 2023-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6686 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612669 [patent_doc_number] => 20230279402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => Aptamers Specific for TLR-4 and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/156936 [patent_app_country] => US [patent_app_date] => 2023-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492866 [patent_doc_number] => 12534730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Compositions and methods for inhibiting GYS2 expression [patent_app_type] => utility [patent_app_number] => 18/156177 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 10 [patent_no_of_words] => 18016 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724290 [patent_doc_number] => 20230338424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy [patent_app_type] => utility [patent_app_number] => 18/154209 [patent_app_country] => US [patent_app_date] => 2023-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154209 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116207 [patent_doc_number] => 12365899 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) [patent_app_type] => utility [patent_app_number] => 18/145218 [patent_app_country] => US [patent_app_date] => 2022-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 33 [patent_no_of_words] => 37464 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483588 [patent_doc_number] => 20230210887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7 MRNA FOR TREATING HEPATITIS B INFECTION [patent_app_type] => utility [patent_app_number] => 18/145791 [patent_app_country] => US [patent_app_date] => 2022-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18145791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693015 [patent_doc_number] => 20230323396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => TETRACYCLINE-INDUCIBLE EXPRESSION SYSTEM [patent_app_type] => utility [patent_app_number] => 18/067686 [patent_app_country] => US [patent_app_date] => 2022-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067686 [rel_patent_id] =>[rel_patent_doc_number] =>)